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Abstract
Background: This study investigated whether patients with acquired haemolytic anaemia (AHA) would have
elevated cancer risk including that for non-haematological solid tumours. We further examined whether the
cancer risk would be different between patients with autoimmune type AHA (AIHA) and patients of non-AIHA.
Methods: Using nationwide population-based insurance claims data of Taiwan we identified a cohort of patients
with AHA with no pre-existing cancer, (n = 3902) and a comparison cohort (n = 39020) without AHA, frequency-
matched by gender, age, urbanization of residency and diagnosis date. Incidence and Cox method estimated
adjusted hazard ratios (aHR) of cancers controlling covariates by the end of 2010 were calculated. Risks between
patients with AIHA and non-AIHA were compared. Sensitivity analysis was carried out to measure the risk of cancer
between patients with and without AHA by follow-up years.
Results: Patients with AHA had a 90 % greater incidence of cancer than controls, with an aHR of 1.78 (95 %
confidence interval (CI), 1.50–2.12)]. The overall aHRs of cancer for patients with AIHA and non-AIHA were 2.01
(95 % CI, 1.56–2.59) and 1.87 (95 % CI, 1.53–2.29), respectively, compared with the comparison cohort. The aHRs
for lymphatic-haematopoietic malignancy were 19.5 and 9.59 in the AIHA and non-AIHA cohorts, respectively. No
hazard of colorectal, lung, liver or breast cancer was significant.
Conclusions: There is a near 2-fold elevated risk for subsequent cancer in patients with AHA, particularly for
lymphatic-haematopoietic malignancy, which is much greater for patients with AIHA than non-AIHA. These
findings can help clinicians decide patient-centred personalized long-term management.
Keywords: Anaemia, Haemolytic, Causality, Non-autoimmune haemolytic anaemia, Retrospective cohort study,
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Background
Acquired haemolytic anaemia (AHA) is the second most
prevalent haemolytic anaemia in clinical medicine after
sickle cell anaemia. With respect to mechanisms, AHA
can be classified on the basis of its pathogenesis: haemoly-
sis due to intracorpuscular defects or extracorpuscular
factors. Paroxysmal nocturnal haemoglobinuria (PNH) is
the only known AHA due to intracorpuscular defects
caused by an acquired somatic mutation. Exogenous
extracorpuscular factors that can cause haemolytic an-
aemia include autoimmune and non-autoimmune factors
such as mechanical destruction, exposure to a toxic agent
or drug and infections. Autoimmune haemolytic anaemia
(AIHA) is the most common form of AHA in the world,
excluding regions where malaria is endemic.
Recent studies have linked acquired idiopathic auto-
immune haemolytic anaemia to an increased risk for fu-
ture haematolymphoproliferative malignancy [1–6]. A
pooled analysis of self-reported autoimmune conditions
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and the risk of non-Hodgkin lymphoma (NHL) from the
InterLymph Consortium demonstrated that a personal
history of haemolytic anaemia was associated with an in-
crease in the risk for NHL [odds ratio (OR), 2.57; 95 %
confidence interval (CI) 1.27–5.21] [5]. In a multivariate
hierarchical regression model, a population-based case–
control study in Scandinavia showed a history of AIHA
was non-significantly associated with an increased risk
of Hodgkin’s lymphoma with an OR of 4.5 (95 % CI,
0.8–24.7) [7].
It has been well-documented that patients with an
autoimmune disease (including idiopathic AIHA) have
an increased risk of malignancy although the mecha-
nisms are still not completely clear. The underlying
autoimmune disorder, with altered lymphocyte reactivity
against self- or exogenous antigens are suspected to be the
main cause [8–10]. Autoimmune disease may present with
secondary AIHA; for example, approximately 5–10 % of
patients with systemic lupus erythematosus (SLE) develop
the secondary AIHA [9].
Other than idiopathic AIHA, which can be regarded
as a disease entity, the remainder of AHA types, includ-
ing secondary AIHA and the entire group of non-
autoimmune AHA (non-AIHA), have various heteroge-
neous aetiologies. The occurrence of non-AIHA may be
a reflection of the characteristics and severity of the
parent disease. Patients with non-AIHA caused by any
aetiology undergo more or less the same treatments tar-
geting the cause of the haemolysis and its complications,
and thus are exposed to potential threats from the use
of corticosteroids, blood component transfusion and
other therapies which may lead to altered immunity. Lit-
tle is known about whether patients with non-AIHA
have a similar or lesser risk for subsequent development
of haematolymphoproliferative malignancies.
We postulated that there is an association between
AHA and an increased risk of malignancy in the future.
Moreover, there is yet a missing piece of information
regarding the estimation of the risk for malignancy,
particularly solid tumours, in patients with AHA. There-
fore, we conducted a nationwide population-based retro-
spective cohort study on patients hospitalised for AHA
and their subsequent cancer risk. We further differenti-




The Taiwan National Health Insurance program has
been a single-payer and universal insurance program
Fig. 1 Study flowchart showing steps for the selection of target populations, exclusion criteria and matching of the comparison cohort in the
nationwide population-based cohort study
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since 1995 and has enrolled almost 99 % of the citizens
of Taiwan in 2007. The Taiwan Ministry of Health and
Welfare authorized the National Health Research Insti-
tutes (NHRI) to manage all registration files and claims
data and to establish the National Health Insurance Re-
search Database (NHIRD). The NHRI created a scram-
bled and anonymous identification number for each
insured person for linking files and to protect the priv-
acy of patients. The NHRI gives the permission to access
the data for qualified researchers. The authors have pub-
lished several population-based studies on the risk of
cancer in various clinical settings using the NHIRD
[11–15]. This study was conducted after the approval
by the Research Ethics Committee of the China Med-
ical University, Taichung, Taiwan (CMU-REC-101-
012). This study was performed in accordance with
the ethical standards of the 1964 Declaration of
Helsinki. The informed consent was waived by the
Research Ethics Committee.
For the purpose of research, specific data subsets were
constructed for more timely distribution. Three relevant
data subsets were chosen for this population-based
study, namely, the Registry for Beneficiaries which con-
tained each insured individual’s registration data such as
gender, date of birth, occupation and coverage period;
the Inpatient Expenditures by Admission which included
original claim data of all inpatients and finally, the Regis-
try for Catastrophic Illness Patient Dataset (RCIPD), a
unique subset of the NHIRD. Inclusion in the RCIPD re-
quired pathologic proof of malignancy, and when in
doubt, the application would be examined by an inde-
pendent haematologist/oncologist medical expense re-
viewer. Patients who satisfied the criteria for the RCIPD
can benefit from a considerable reduction in out-of-
pocket expenses for their cancer care throughout the
country; this may also create a second check-point con-
trol from the patient side to prevent under-reporting of
cancer occurrence in the RCIPD. In this research, the
disease history was assembled from the Inpatient file.
The disease diagnosis was recorded as per the Inter-
national Classification of Diseases, Ninth Revision, Clin-
ical Modification (ICD–9-CM).
Study population
We organized a population-based retrospective cohort
study to investigate the association between AHA and
subsequent cancer risk. The flow chart of the study
population selection is shown in Fig. 1. The AHA cohort
consisted of patients with newly-diagnosed AHA (ICD-
9-CM 283, from the inpatient records from 2000 to
2008. The index date was set at six months after (the
first episode if more than one) the diagnosis of AHA
was given at the hospital discharge. Patients with pre-
existing malignancy before the index date were excluded.
The AHA patients were separated into two sub-cohorts:
a non-AIHA sub-cohort (ICD-9-CM codes, 283.1, 283.2
and 283.9) and an AIHA sub-cohort (ICD-9-CM code =
283.0). Because of the nature of an ICD-9-CM diagnosis
categorization, a drug-induced haemolytic event in a
patient with glucose-6-phosphate dehydrogenase (G6PD)
deficiency would be coded as inherited haemolytic an-
aemia and thus was not included in the studied co-
hort of AHA.
The comparison cohort comprised individuals who
had not been diagnosed with AHA or pre-existing
cancer from 2000 to 2008. In order to increase the
statistical power, for each AHA patient, we randomly
selected 10 comparison persons from the general
population frequency-matched by age (per 5 years),
gender, urbanization of residency and index date. The
Table 1 Baseline demographic data and comorbidity compared
between the comparison and the acquired haemolytic anaemia
(AHA) cohorts
Variable Comparison cohort
n = 39020 (%)
AHA cohort
n = 3902 (%)
Age, years (SD) 42.3 (25.4) 42.3 (25.5)
< 20 8920 (22.9) 892 (22.9)
20–39 9200 (23.6) 920 (23.6)
≥ 40 20900 (53.6) 2090 (53.6)
Sex
Female 22230 (57.0) 2223 (57.0)
Male 16790 (43.0) 1679 (43.0)
Urbanization of residency
1 (highest) 9360 (24.0) 936 (24.0)
2 12990 (33.3) 1299 (33.3)
3 6260 (16.0) 626 (16.0)
4+ (lowest) 10410 (26.7) 1041 (26.7)
Type of AHA
Autoimmune 0 1246 (31.9)
Non-immune 0 2656 (68.1)
Comorbidity
Diabetes 2716 (7.0) 499 (12.8)
SLE 18 (0.05) 263 (6.7)
Alcohol-use disorder 147 (0.4) 76 (1.9)
Splenomegaly 25 (0.1) 130 (3.3)
CKD 171 (0.4) 247 (6.3)
Liver cirrhosis 161 (0.4) 139 (3.6)
RA 63 (0.2) 37 (0.9)
HBV 108 (0.3) 72 (1.8)
HCV 99 (0.3) 94 (2.4)
Abbreviations: AHA acquired haemolytic anaemia, CKD chronic kidney disease,
HBV hepatitis B virus infection, HCV hepatitis C virus infection, RA rheumatoid
arthritis, SD standard deviation, SLE systemic lupus erythematosus
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index date of the comparison person was randomly
matched by the same index year as that of the AHA
case. The comparison cohort also had the same half
year of lag observation time. We excluded all individ-
uals with cancer diagnosed before the index date. The
main parameter under consideration in this study was
the incidence of developing cancer (ICD-9-CM 140–
208, from the RCPID). The follow-up was terminated
when cancer developed, or censored when the patient
withdrew from the insurance, lost to follow-up or de-
ceased, or on 31st December 2010 (Fig. 1).
The study also collected the co-morbidity history for
each study subject as confounding factors. The co-
morbidities before the index date included diabetes mel-
litus (DM, ICD-9-CM 250), alcohol use disorders (ALD,
ICD-9-CM 265.2, 291, 303, 305.0, 357.5, 425.5, 535.3,
571.0, 571.1, 571.2, 571.3, 980.0 and V11.3), chronic kid-
ney disease (CKD, ICD-9-CM 585), splenomegaly (ICD-
9-CM 289.4), liver cirrhosis (ICD-9-CM 571.2, 571.5 and
571.6), hepatitis B virus infection (HBV, ICD-9-CM
070.2, 070.3 and V02.61) and hepatitis C virus infection
(HCV, ICD-9-CM V02.62, 070.41, 070.44, 040.51 and
070.54) from the inpatient file and systemic lupus ery-
thematosus (SLE, ICD-9-CM 710.0) and rheumatoid
arthritis (RA, ICD-9-CM 714) from the RCPID. The
urbanization level of residency was based on several
index including population density (people/km2), and
population ratio of different educational levels, popu-
lation ratio of elderly, population ratio of people of
agriculture workers and the number of physicians per
100,000 people [16]. We categorized the urbanization
of residency into 4 levels. The level 1 indicated the
highest urbanization level and the level 4+ meant the
lowest level.
Statistical analysis
We compared distributions of age group, gender and co-
morbidities and the mean and standard deviation (SD)
for age between AHA and comparison cohorts. We cal-
culated the overall incidence density rates of cancer for
both cohorts, using the total number of cancer events
divided by the total sum of follow-up years for each co-
hort. Cox proportional hazards regression analysis was
used to estimate the AHA cohort to the comparison co-
hort hazard ratio (HR) and 95 % confidence interval.
Multivariable Cox model was used to calculate the ad-
justed hazard ratio (aHR) and 95 % confidence interval
including sex, age, urbanization of residency and all co-
morbidities in the model. Further data analysis calcu-
lated the incidence of individual cancer and the related
AHA cohort to comparison cohort aHR for major can-
cers, including cancers of lung (ICD-9-CM 162), liver
(ICD-9-CM 155), colorectal (ICD-9-CM 153 and 154),
breast (ICD-9-CM 174, only in female), lymphatic and
hematopoietic tissue(ICD-9-CM 200–208) and others.
We also used Kaplan-Meier method to measure and plot
the cumulative incidence for both cohorts and used log-
rank test to examine the difference between the 2 co-
horts. The proportional hazards assumption was not vio-
lated in the scaled Schoenfeld residuals test (p = 0.21).
SAS 9.3 software (SAS Institute, Cary, NC, USA) was
used to manage and analyse the data. The cumulative
Fig. 2 The cumulative incidence of cancer in the study cohorts
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Table 2 Incidence of cancer and stratified analysis with adjusted hazard ratios by multivariate Cox proportional hazards regression
analysis for study cohort
Variable Event PYs Rate Crude HR (95 % CI) Adjusted HR (95 % CI)
AHA
No 1130 206599 54.7 ref ref
Yes 187 17912 104 1.92(1.64–2.24) 1.78(1.50–2.12)
Non-Autoimmune AHA 119 12107 98.3 1.81(1.50–2.19) 1.87(1.53–2.29)
Autoimmune AHA 68 5805 117 2.15(1.68–2.75) 2.01(1.56–2.59)
Age group
< 25 9 55421 1.62 ref ref
25–39 54 52892 10.2 6.32(3.12–12.8) 6.78(3.35–13.7)
≥ 40 1254 116197 108 66.9(34.7–129) 65.37(33.9–126)
Sex
Female 606 127460 47.5 ref ref
Male 711 97051 73.3 1.54(1.38–1.71) 1.50(1.34–1.67)
Urbanization of residency
1 (highest) 282 53113 53.1 ref ref
2 446 77556 57.5 1.08(0.93–1.25) 0.99(0.85–1.14)
3 185 34097 54.3 1.02(0.85–1.23) 1.12(0.93–1.34)
4+ (lowest) 404 59745 67.6 1.27(1.09–1.48) 1.08(0.93–1.26)
Comorbidity
DM
No 1128 210752 53.5 ref ref
Yes 189 13759 137 2.61(2.24–3.05) 1.29(1.10–1.51)
SLE
No 1309 223337 58.6 ref ref
Yes 8 1174 68.2 1.18(0.59–2.37) 1.04(0.51–2.12)
Alcohola
No 1297 223606 58.0 ref ref
Yes 20 905 221 3.88(2.49–6.04) 1.09(0.66–1.81)
Splenomegaly
No 1303 223914 58.2 ref ref
Yes 14 597 235 4.10(2.42–6.94) 1.50(0.85–2.66)
CKD
No 1284 223018 57.6 ref ref
Yes 33 1493 221 3.91(2.77–5.52) 1.54(1.08–2.21)
Liver cirrhosis
No 1278 223469 57.2 ref ref
Yes 39 1042 374 6.71(4.88–9.24) 1.96(1.30–2.94)
RA
No 1314 224077 58.6 ref ref
Yes 3 434 69.1 1.2(0.39–3.71) 0.79(0.25–2.47)
HBV
No 1303 223738 58.2 ref ref
Yes 14 773 181 3.15(1.86–5.33) 1.38(0.80–2.38)
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incidence curve was plotted by SPSS. The significant
level was set at less than 0.05 for two-side testing of
p-value.
Results
We finally enrolled 3,902 AHA patients and 39,020
healthy individuals for comparison with similar mean
age (42 years) and sex ratio (male: 43 %) (p > 0.05) in this
study (Table 1). The proportion of AIHA in the AHA
cohort was 32 %.
Amongst the patients with AHA, 13 % had diabetes
mellitus, 7 % had SLE and 6 % had chronic kidney dis-
ease. The proportions of the comorbidities in AHA co-
hort were higher than the proportions in comparison
cohort (p < 0.0001).
The cumulative incidence of cancer after 11-year
follow-up measured by Kaplan-Meier method was 3.9 %
greater in the AHA cohort than in the comparison co-
hort (log-rank test, p < 0.0001; Fig. 2).
During a total of 17,912 patient-years for the AHA co-
hort under observation, 187 cancers occurred. Table 2
shows that the incidence density of cancer was 1.9-fold
greater in the AHA cohort than in the comparison co-
hort (104 vs. 54.7 per 10,000 person-years) with an
adjusted HR of 1.78 (95 % CI = 1.56–2.59) in the multivar-
iable Cox proportional hazards regression analysis. Re-
garding the subtypes, compared with the individual
without AHA, there were increased hazard of developing
cancer for both non-AIHA patients (HR = 1.87, 95 % CI =
1.53–2.29) and AIHA patients (HR = 2.01, 95 % CI =
1.56–2.59), respectively. In this study, male gender [ad-
justed HR (aHR) 1.50, 95 % CI = 1.34–1.67)], DM (1.29,
1.10–1.51), CKD (1.54, 1.08–2.21), liver cirrhosis (1.96,
1.30–2.94) and infection with HCV (2.78, 1.89–4.08) were
significantly associated with an increased risk of cancer.
Table 3 shows the development of different types of
cancer between the AHA and comparison cohorts.
Overall, relative to the individuals without AHA, the pa-
tients with AHA were significantly associated with an in-
creased risk of lymphatic and haematopoietic (HR =
13.1, 95 % CI = 8.46–20.3) and other malignant solid tu-
mours (HR = 1.82, 95 % CI = 1.40–2.35). Patients with
non-AIHA and AIHA had near 10-fold (HR = 9.59, 95 %
CI = 5.57–16.5) and 20-fold (HR = 19.5, 95 % CI = 11.5–
32.8) increased risk of lymphatic and haematopoietic tu-
mours, respectively.
Table 4 shows the sensitivity analysis conducted for
the risk of cancer between the AHA and comparison co-
horts by follow-up years. The results suggested that pa-
tients with AHA were associated with a significantly
increased risk of developing cancer as compared with in-
dividuals without AHA, although all of the study popu-
lation had at least four years of follow-up.
Discussion
This nationwide population-based retrospective frequency-
matched cohort study with 17,919 patient-years follow-up
for the entire AHA cohort had an approximately 80 %
increase in the hazard for subsequent malignancy as
compared with the non-AHA comparators. The
randomly-selected comparison cohort was matched for
age, gender, urbanization of residency and index date.
Confounding factors such as type 2 diabetes, alcohol-
use disorder, splenomegaly, chronic kidney disease,
Table 2 Incidence of cancer and stratified analysis with adjusted hazard ratios by multivariate Cox proportional hazards regression
analysis for study cohort (Continued)
HCV
No 1286 223814 57.5 ref ref
Yes 31 697 445 7.99(5.59–11.4) 2.78(1.89–4.08)
Adjusted model was mutually adjusted
Abbreviations: AHA acquired haemolytic anaemia, Alcohola alcohol-use disorders, CI confidence interval, CKD chronic kidney disease, HBV hepatitis B virus infection,
HCV hepatitis C virus infection, HR hazard ratio, PYs person-years, Rate incidence rate, per 10,000 person-years, RA rheumatoid arthritis, ref reference, SLE systemic
lupus erythematosus
Table 3 Incidence of different types of cancer and measured hazard ratios by multivariate Cox proportional hazards regression
analysis for study cohorts
Cancer type Liver Lung Colorectal Lymphatic and haematopoietic tissue Breast Others
HR (95 % CI) HR (95 % CI) HR (95 % CI) HR (95 % CI) HR (95 % CI) HR (95 % CI)
Comparison cohort ref ref ref ref ref ref
AHA cohort 1.23(0.77–1.98) 1.28(0.73–2.23) 1.16(0.65–2.07) 13.1(8.46–20.3) 1.13(0.55–2.30) 1.82(1.40–2.35)
Non-AIHA 1.43(0.84–2.43) 1.24(0.62–2.46) 1.28(0.65–2.50) 9.59(5.57–16.5) 1.23(0.53–2.88) 1.81(1.34–2.46)
AIHA 0.91(0.41–2.01) 1.35(0.55–3.30) 0.95(0.35–2.61) 19.5(11.5–32.8) 0.98(0.34–2.85) 1.82(1.22–2.73)
Model adjusted for age, sex, urbanization of residency, DM, SLE, alcohol-use disorders, splenomegaly, CKD, liver cirrhosis, HBV, HCV and RA
Abbreviations: AHA acquired haemolytic anaemia, CKD chronic kidney disease, DM diabetes mellitus, HBV hepatitis B virus infection, HCV hepatitis C virus infection,
RA rheumatoid arthritis, ref reference, SLE Systemic Lupus Erythematosus
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rheumatoid arthritis, history of viral hepatitis B or C
infection and liver cirrhosis were adjusted in the
construction of the Cox model. Not only did the risk
increase in patients with AIHA (aHR = 2.01) but it also
increased in patients with non-AIHA (aHR = 1.87) that
had resulted from a group of heterogeneous aetiologies.
To the best of our knowledge, this study provided for
the first time the evidence for and the best estimate of
the risk for subsequent cancer in patients with non-
autoimmune haemolytic anaemia.
In this study, the sensitivity analysis conducted to help
understand whether the risk would still persist after up
to four years of follow-up demonstrated that the aHR
was still around 1.75 beyond the fifth year of the follow-
up. This sensitivity analysis helped exclude the possi-
bility of protopathic bias (reverse causation) because
some haematolymphoproliferative disorders may go
unnoticed for years. In the literature, a pooled ana-
lysis of the InterLymph Consortium accrued 29,423
participants from 12 case–control studies and com-
puted the pooled odds ratios at 2.5 (95 % CI, 1.08–
5.83) in a joint fixed-effect model for the future
development of non-Hodgkin’s lymphoma ten years
after a self-reported history of haemolytic anaemia
[5]. It has been noted that the use of self-reported
history of haemolytic anaemia had an inherent risk
for exposure misclassification bias.
The risk for lymphatic-haematopoietic malignancy was
increased in both the AIHA (19.5-fold) and non-AIHA
(9.6-fold) sub-cohorts in this study. Anderson et al. re-
ported the magnitude of the association in terms of odds
ratio of AIHA and chronic myeloproliferative disorder
(CMPD) (excluding chronic myeloid leukaemia) to be
11.9 (4.72–30.2); however, after excluding claims within
5 years of CMPD diagnosis, the OR became statistically
insignificant (OR, 4.02; 95 % CI, 0.50–32.5) [17]. In the
same study, they also demonstrated a significant associ-
ation between AIHA and acute myeloid leukaemia (OR,
3.74; 95 % CI, 1.94–7.22), chronic myeloid leukaemia
(OR, 5.23; 95 % CI, 1.82–15.0), and myelodysplastic syn-
dromes (OR, 4.12; 95 % CI, 1.66–10.2).
This study also revealed that the risk for lymphatic-
haematopoietic malignancies and for certain malignant
solid tumours increased. Individuals of the entire AHA
cohort had an increased risk for solid tumours other
than those occurring in the liver, lung, colorectal and
breast.
The linkage datasets methodology utilized in the in-
vestigation of cancer incidence in this cohort study pro-
duced robust and reliable results because of the use of
the unique registry dataset of severe illnesses such as
cancer that offered a second check mechanism for can-
cer diagnosis ascertainment. It is noteworthy that this
study also captured the outcomes of the risk for subse-
quent total cancer occurrence in individuals with dia-
betes mellitus (aHR 1.29; range, 1.10–1.51), chronic
kidney disease (aHR 1.54; range, 1.08–2.21), liver cirrho-
sis (aHR 1.96; range, 1.30–2.94), and HCV infection
(aHR 2.78; range, 1.89–4.08), which were in-line with
the current understanding of these risks from the litera-
ture [18–22].
It may be an oversimplification to attribute the mecha-
nisms for the positive association with future malignan-
cies in patients with non-AIHA solely to the most feared
complication resulting from prior exposure to cortico-
steroid therapy for controlling haemolytic anaemia and
its underlying systemic disorder. The authors speculated
that perhaps haemolysis itself will alter the circulating
concentrations of angiogenic and pro-inflammatory
markers which could contribute to the increased cancer
risk [23–25].
Utilizing the coding from the discharge diagnoses to
capture the occurrence of AHA and medical co-
morbidities has been regarded as more reliable than the
use of the outpatient billing records because billings
using the discharge diagnoses will go through the hands
of qualified medical coding specialists [26]. Nevertheless,
the potentials for inaccurate ICD-9-CM coding may
exist for any administrative claims-based research. A few
of the limitations of this study must be noted. Owing to
the de-identified nature of each claim record in the data-
sets, a chart review of the patient’s medical record was
Table 4 Sensitivity analysis showing varying estimates of the adjusted risk of developing subsequent cancer utilizing a Cox model
by different cut-offs in lengthening the time lag for follow-up
Comparison cohort AHA cohort Crude HR
(95 % CI)
Adjusted HR
(95 % CI)Variable Event PYs rate Event PYs rate
Time lag (year)
> 1 961 206171 46.6 138 17765 77.7 1.70(1.42–2.04) 1.69(1.39–2.05)
> 2 771 200747 38.4 106 17131 61.9 1.67(1.36–2.04) 1.68(1.35–2.10)
> 3 610 187711 32.5 82 15680 52.3 1.66(1.32–2.09) 1.70(1.32–2.19)
> 4 433 170395 25.4 61 13926 43.8 1.78(1.36–2.33) 1.75(1.30–2.36)
Model adjusted for age, sex, urbanization of residency, DM, SLE, alcohol-use disorders, splenomegaly, CKD, liver cirrhosis, HBV, HCV and RA
Abbreviations: AHA acquired haemolytic anaemia, CI confidence interval, HR hazard ratio, PYs person-years, rate incidence rate, per 10,000 person-years
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not possible. In addition, the datasets from the NHIRD
did not contain biological data such as height, weight
and smoking history or serial hemogram data so that the
severity of haemolytic anaemia could not be determined.
These limitations may potentially affect the risk esti-
mates in this study.
Conclusions
In conclusion, the adjusted hazard ratio for lymphatic-
haematopoietic malignancy was elevated for 20-fold in
the AIHA group and for 10-fold in the non-AIHA
group. This study also provided the risk estimates for fu-
ture solid tumour occurrence in patients with acquired
haemolytic anaemia, particularly of malignant solid tu-
mours other than those occurring in the lung, colorec-
tum, liver and breast (80 % increased risk).
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